On November 11, the XIII All-Russian Forum “Issues of Emergency Cardiology - 2020” was launched, which is supported by the Ministry of Health of the Russian Federation and the RPO “Society of Specialists in Emergency Cardiology”.
The Forum is being held for the thirteenth time, this year, due to the epidemiological situation, the Forum events are held online. The Forum agenda has a scientific and practical focus in the field of emergency cardiology and covers all aspects of the organization and implementation of patient care.
It is difficult to overestimate the relevance and theme of the Forum, especially considering the important tasks set for the national medicine within the framework of the National Project “Healthcare”. First of all - to increase the life expectancy of citizens of our country. The program of the forum includes lectures, scientific and practical seminars, analyzes of clinical cases, within the framework of which the latest achievements in the field of urgent cardiology will be presented.
As part of the material and technical aspects of urgent cardiac care and the introduction of innovative technologies, NANOLEK will present Efferon columns for hemosorption. Extracorporeal blood detoxification has a positive effect on a number of fundamental factors that determine the severity of the course and prognosis in patients with severe angina pectoris and acute myocardial infarction. Methods of extracorporeal detoxification of blood can significantly reduce the severity of the syndrome of endogenous intoxication, remove toxins of average molecular weight, which has a beneficial effect on the clinical progression of the disease and objective indicators of the state of the cardiovascular system.
The Forum is open for public, registration for online participation on the website:https://www.em-cardio.ru/
Company and product information
NANOLEK is a modern fast-evolving Russian biopharmaceutical company with its own high-tech complete cycle production compliant with GMP and ISO standards. NANOLEK specialises in the production of import-substituting and innovative pharmaceuticals, both in-house developed and invented with the help of international partners, focusing on the prevention and treatment of socially significant diseases. The company has unique experience in the area of transfer of technologies as part of partnership with the leading international pharmaceutical companies (Merck, Sanofi, Novartis, Egis, Celltrion, Riemser, etc.)
LLC Nanolek took the first place in the category “Fast-growing large companies” of the rating “TECHUSPEH”-2019, and the company was also a member of the priority project of the Ministry of Economic Development of Russia “Support of Leading Private High-Tech Companies” (“National Champions”) in 2017.
In April 2020, Nanolek announced the start of a strategic partnership with Efferon JSC to actively launch special medical products for the treatment of “cytokine storms”, sepsis and septic shock.
Efferon JSC was founded by graduates of the Faculty of Chemistry of Moscow State University named after M.V. Lomonosov and the INEOS RAS named after A.N. Nesmeyanov in 2017. The company is a resident of the Science Park of Moscow State University and the Skolkovo Foundation Biomedical Cluster. It has developed and is now producing two new medical devices - Efferon CT absorption columns for the treatment of cytokine storm syndrome and acute respiratory distress syndrome (ARDS), and Efferon LPS for the treatment of sepsis and septic shock. Both medical devices received market authorization granted by Roszdravnadzor and are approved for use in clinical practice. The columns have already been successfully tested on the basis of the Lomonosov Moscow State University Medical Scientific and Educational Center, City Clinical Hospital No. 67 named after L. A. Vorokhobov, City Clinical Hospital No. 1 named after N.I. Pirogov, Infectious Disease Clinic No. 2, National Medical Research Center of Oncology (Rostov-on-Don) and many other advanced medical institutions.